

Jagat Pharma gets WHO-GMP, CoPP certification for Isotine Plus ayurvedic eye drops

Jagat Pharma gets WHO-GMP, CoPP certification for Isotine Plus ayurvedic eye drops

DELHI, DELHI, INDIA, May 25, 2023 /EINPresswire.com/ -- In a major feat to establish itself as one of the leading companies in Ayurveda, Uttar Pradesh-based Jagat Pharma has now been accredited with the WHO-GMP (World Health Organization - Good Manufacturing Practices) certificate and Certificate of Pharmaceutical Products (CoPP) for its groundbreaking invention – the Isotine Plus ayurvedic eye drops.

This is the first time any Ayurvedic eye drop manufactured in the country has received the WHO-GMP certificate and (CoPP) certificate. Today Jagat Pharma stands out and has placed itself amongst the handful of manufacturing units of Ayurvedic products to have achieved this quality benchmark.

The Isotine Plus ayurvedic eye drops by Jagat Pharma have been clinically used for 36 years with a track record to reverse cataract-induced visual impairment. The eye drops are used to treat complex eye diseases like Cataracts, Macular Degeneration,



Myopia, Hypermetropia, Glaucoma, Diabetic Retinopathy, Retinitis Pigmentosa, etc. Some of the most unique ayurvedic ingredients used in the Isotine Plus ayurvedic eye drops include Chandan (*Santalum album*), Apamarg (*Achyranthes aspera*), Fennel (*Foeniculum vulgare*), Punarnava (*Boerhaviadiiffusa*), Bhingaraj (*Ecliptaprostrata*), Arjuna (*Terminalia arjuna*), and Satva Pudina (*Mentha piperita*), to name a few.

“We are indeed elated to have been accredited by the WHO-GMP certification and CoPP Certificate, which is a hallmark of best manufacturing practices. Our aim has always been to continue advanced medicinal research and come up with products which will provide the best medical benefit to the maximum number of people. The World Health Organization recognizing our dedicated efforts is an encouragement for us to put even more focus on research and innovation,” said Dr Mandeep Singh Basu, Director of Jagat Pharma.

Jagat Pharma has conducted clinical trial on Isotine Plus eye drop in patients suffering from immature cataract and other complex eye problems - An open-label, comparative multi-centric, two-arm, and interventional study was conducted under the CTRI Registration no-CTRI/2021/01/030699 (registered on 22/01/2021). The trial, which included 70 patients, was conducted for 6 months and showed a significant reduction in cataract grade (from grade II to grade I) and improvement in the cases of immature cataract. Isotine Plus eye drop was found to be safe on regular long-term use.

Recently, Jagat Pharma announced the results of a retrospective observational study conducted by Prof. Yamini of Banaras Hindu University, Uttar Pradesh, on the use of Isotine Plus ayurvedic eye drops. The study, which included 308 cataract patients, treated during 2017 to 2019, showed a significant improvement in uncorrected distance visual acuity (UDVA) and uncorrected near visual acuity (UNVA) after treatment with Isotine Plus.

With growing popularity and impressive outcomes, around 10 lakh units of the Isotine Plus Ayurvedic eye drops have been sold during 2022-2023. Presently, Jagat Pharma is exporting the Isotine Plus eye drops to Cambodia and Russia and the company has plans to expand its export business to other nations like Germany, Hong Kong, Japan, UAE, Thailand and Taiwan.

Sana
TYCC
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/635526198>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.